TABLE 1.
H. pyloria | n |
rrl genotype |
gyrA genotype |
||||
---|---|---|---|---|---|---|---|
Wild type | Missense mutation | No data | Wild type | Missense mutation | No data | ||
Phase 1 | |||||||
Development panel H. pylori strains | 126 | ||||||
CLA-R | 40 | 3b | 37 | ||||
CLA-S | 86 | 86 | 0 | ||||
FQ-R | 21 | 0 | 21 | ||||
FQ-S | 105 | 105c | 0 | ||||
Phase 2 | |||||||
Clinical H. pylori strains | 92 | ||||||
CLA-R | 48 | 2 | 34 | 12 | |||
CLA-S | 44 | 21 | 1 | 22 | |||
FQ-R | 41 | 41 | |||||
FQ-S | 51 | 51 | |||||
Gastric biopsy specimens | 105 | ||||||
CLA-R | 49 | 0 | 49 | ||||
CLA-S | 56 | 56 | 10 | ||||
FQ-R | 26 | 26 | |||||
FQ-S | 79 | 79 |
CLA, clarithromycin; FQ, fluoroquinolone; S, susceptible; R, resistant.
Clarithromycin MIC, 2 μg/ml.
Sixteen strains harbored a Thr87, which confers fluoroquinolone susceptibility.